Suppr超能文献

在浸润性脑肿瘤模型中,用靶向肿瘤微环境的低密度脂蛋白受体(LDLR)配体肽偶联金纳米颗粒增强质子治疗。

Enhanced proton treatment with a LDLR-ligand peptide-conjugated gold nanoparticles targeting the tumor microenvironment in an infiltrative brain tumor model.

作者信息

Seo Seungjun, Kim Eun Ho, Chang Won-Seok, Lee Won-Seok, Kim Ki-Hwan, Kim Jong-Ki

机构信息

Biomedical Engineering, School of Medicine, Daegu Catholic University Daegu, South Korea.

Biochemistry, School of Medicine, Daegu Catholic University Daegu, South Korea.

出版信息

Am J Cancer Res. 2022 Jan 15;12(1):198-209. eCollection 2022.

Abstract

The tumor microenvironment (TME) of glioblastoma malforms (GBMs) contains tumor invasiveness factors, microvascular proliferation, migratory cancer stem cells and infiltrative tumor cells, which leads to tumor recurrence in the absence of effective drug delivery in a Blood Brain Barrier (BBB)-intact TME and radiological invisibility. Low-density lipoprotein receptor (LDLR) is abundant in the blood brain barrier and overexpressed in malignant glioma cells. This study aimed to treat the TME with transmitted proton sensitization of LDLR ligand-functionalized gold nanoparticles (ApoB@AuNPs) in an infiltrative F98 glioma rat model. BBB-crossing ApoB@AuNPs were selectively taken up in microvascular endothelial cells proliferation and pericyte invasion, which are therapeutic targets in the glioma TME. Proton sensitization treated the TME and bulk tumor volume with enhanced therapeutic efficacy by 67-75% compared to that with protons alone. Immunohistochemistry demonstrated efficient treatment of endothelial cell proliferation and migratory tumor cells of invasive microvessels in the TME with saving normal tissues. Taken together, these data indicate that the use of LDLR ligand-functionalized gold nanoparticles is a promising strategy to treat infiltrative malignant glioma while overcoming BBB crossing.

摘要

胶质母细胞瘤(GBM)的肿瘤微环境(TME)包含肿瘤侵袭因子、微血管增殖、迁移性癌症干细胞和浸润性肿瘤细胞,这会导致在血脑屏障(BBB)完整的TME中缺乏有效药物递送时肿瘤复发以及影像学上的不可见性。低密度脂蛋白受体(LDLR)在血脑屏障中含量丰富,且在恶性胶质瘤细胞中过表达。本研究旨在利用LDLR配体功能化金纳米颗粒(ApoB@AuNPs)的透射质子敏化作用,在浸润性F98胶质瘤大鼠模型中治疗TME。能够穿越血脑屏障的ApoB@AuNPs被选择性摄取到微血管内皮细胞增殖和周细胞浸润部位,这些部位是胶质瘤TME中的治疗靶点。与单独使用质子相比,质子敏化作用治疗TME和实体瘤体积的疗效提高了67 - 75%。免疫组织化学显示,该治疗有效作用于TME中侵袭性微血管的内皮细胞增殖和迁移性肿瘤细胞,同时保留了正常组织。综上所述,这些数据表明,使用LDLR配体功能化金纳米颗粒是一种有前景的治疗浸润性恶性胶质瘤同时克服血脑屏障穿越问题的策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验